Derfor stiger SLS-aktien før markedet åbner: SELLAS Life Sciences sætter REGAL fase 3-nedtælling tilbage i spil
SELLAS Life Sciences rose 3.4% to $4.29 in premarket trading Monday after closing at $4.15 Friday. The company is nearing the final analysis of its phase 3 AML trial, with 72 of 80 required events recorded as of late December. SELLAS reported $71.8 million in cash at year-end, plus $26.5 million from warrant exercises. Short interest stands at 41.33 million shares, or 24.42% of the float.